PDF-CLINICAL PATHWAY

Page 1of 13PENICILLIN ALLERGY DELABELING ALGORITHMHistory PhysicalPCN allergy identifiedOnly do test dose during day shift and if a Parentguardian is present if not you can Inclusion CriteriaAdmitte. Combined Section Meeting 2015. February 4. th. -7. th. , 2015 – Indianapolis, IN. PHALAN BOLDEN RN, MSN FNP-CMC MAIN. LATASHA RUFFIN PT, DPT CMC-MAIN. DISCLAIMER. There is no relationship that can reasonably be viewed as creating a conflict of interest, or the appearance of a conflict of interest that might bias the content of the presentation. Nor is there any significant financial interest in any product instrument, device, service or material discussed in the presentation including the source of any third party compensation related to the presentation. . Objectives. Demonstrate . an understanding of the NSTEMI clinical pathway.. Understand the importance of . early and consistent . education throughout hospital stay.. Demonstrate . the knowledge of . Stirling Bryan, PhD. Graham Scotland, PhD. Mohsen Sadatsafavi, . PhD. Overview of session. Stirling Bryan:. In Search of Efficiency, Consistency, Fairness, and Impact in . HTA. Graham Scotland. Modelling screening and treatment pathways for diabetic retinopathy. Combined Section Meeting 2015. February 4. th. -7. th. , 2015 – Indianapolis, IN. PHALAN BOLDEN RN, MSN FNP-CMC MAIN. LATASHA RUFFIN PT, DPT CMC-MAIN. DISCLAIMER. There is no relationship that can reasonably be viewed as creating a conflict of interest, or the appearance of a conflict of interest that might bias the content of the presentation. Nor is there any significant financial interest in any product instrument, device, service or material discussed in the presentation including the source of any third party compensation related to the presentation. . Antonius Schuh, Ph.D. | . Chief Executive Officer. September . 2013. Forward-Looking Statements. Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product and test development, test transfer to contracting labs, government regulation, market acceptance, limited commercial experience, dependence on key personnel, obtaining financing and other factors discussed in the Company's periodic reports filed with the Securities and Exchange Commission.. Page 1 of 19 !If after hours/weekend, refer to NICU(call CHCO OneCall to request NICU consultation) Infant at birth Provider to complete:Airway assessmentFeeding and growth assessment Call Cleft RN Page 1 of 12 CONCUSSION Age 6 to 18 yearsALGORITHM Triage AssessmentTargeted history and examVital signsNeuro check with pupil examRequest immediate clinician evaluation if clinical concern or signi Page 1 of 13 VIRAL CROUPALGORITHM: Outpatient/ED Management Inclusion Criteria Previously healthy Age 6 months to 6 years Exclusion Criteria Symptoms suggestive of an alternative diagnosis Known up Page 1 of 15 Diabetic Ketoacidosis (DKA) TreatmentALGORITHM Algorithm for the Management of Diabetic Ketoacidosis (DKA) Immediate Assessment : Place patient on full cardio/respiratory (CR) monitor Page 1 of 13 PROTEIN ENERGY MALNUTRITION (FAILURE TO THRIVE)ALGORITHM Inclusion criteria Conduct Initial AssessmentHistory and physical (Weight height, : edema Consider basic labs based on H&(recomm Page 1 of 20 RISK SPINAL FUSAlgorithm 1: Preoperative Inclusion Criteria Patients having spine surgery without other complex chronic conditions Exclusion Criteria High - risk spinal fusion patien Page 1 of 12 URINARY TRACT INFECTION (UTI)ALGORITHMUTI Testing Age �36months or Toilet Trained Age 60days-36months Age Intended for: Clean Catch UA Fever? Gender? Circumcised? Male Female N Nanosimilars. Beat . Flühmann. Global Lead NBCD . Vifor. . Pharma. Ltd. Steering. committe . member. . of. . the. NBCD Working Group. NBCD:. A. n increasingly important drug class. 2. Nanosimilars. with. Amelia Randle, SWAG Clinical Director, and. Louise Hunt, Consultant Colorectal Surgeon, . Somerset Foundation Trust . 17.09.2020. Agenda. Agenda Item. Welcome and Introduction. Dr Amelia Randle, Clinical Director, SWAG Cancer Alliance.